Copolymer-1 in the treatment of multiple sclerosis

What Was Tested

The paper reports a study of Glatiramer Acetate in the context of multiple sclerosis, published as a randomized controlled trial.

Recent research in the treatment of multiple sclerosis (MS) has yielded new therapies.

Who Took Part

The abstract describes 251 patients taking part.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

The patients were allocated by chance, so the Glatiramer Acetate group and the comparison group should start out alike.

As a double-blind Glatiramer Acetate study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Glatiramer Acetate, giving a reference point.

More than one site took part, so the patients came from several places.

What Was Measured

PubMed files the paper under topics including Glatiramer Acetate, Immunosuppressive Agents, Multiple Sclerosis and Peptides.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glatiramer Acetate in 251 patients in people with multiple sclerosis.

The publication is from 1998 (The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses), a journal based in United States.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.